Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MannKind Corp MNKD

Healthcare Biotechnology
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the... see more

Recent & Breaking News (NDAQ:MNKD)

MannKind CEO Alfred Mann to Transition to Executive Chairman; COO and President Hakan Edstrom Appointed to CEO

GlobeNewswire January 12, 2015

MannKind Earns $50 Million in Milestone Payments From Sanofi

GlobeNewswire January 8, 2015

MannKind Earns $50 Million in Milestone Payments From Sanofi

GlobeNewswire January 8, 2015

MannKind Corporation to Present at the J.P. Morgan 2015 Healthcare Conference

GlobeNewswire January 7, 2015

MannKind Corporation to Present at The 26th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 25, 2014

MannKind Corporation Reports 2014 Third Quarter Financial Results

GlobeNewswire November 3, 2014

MannKind Corporation to Hold 2014 Third Quarter Financial Results Conference Call on November 3, 2014

GlobeNewswire October 27, 2014

MannKind Announces Receipt of $150 Million Licensing Upfront Payment

GlobeNewswire September 29, 2014

MannKind Announces Closing of Global Licensing Agreement With Sanofi

GlobeNewswire September 24, 2014

Oramed's Insulin Pill Superior to New Diabetes Drugs Gaining Approval

Accesswire September 11, 2014

MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference

GlobeNewswire September 2, 2014

MannKind Corporation (MNKD) Drops 12.31% on August 12

Equities.com August 12, 2014

eResearch Highlights NASDAQ Volume Leaders for Monday, August 11

Accesswire August 12, 2014

MannKind Corporation Reports 2014 Second Quarter Financial Results

GlobeNewswire August 11, 2014

Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin

PR Newswire August 11, 2014

Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin

GlobeNewswire August 11, 2014

MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014

GlobeNewswire August 5, 2014

MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes

GlobeNewswire June 27, 2014

MannKind to Present at Upcoming Conferences

GlobeNewswire May 27, 2014

MannKind Corporation Reports 2014 First Quarter Financial Results

GlobeNewswire May 12, 2014